Patient Controlled Injectors Market Forecast to 2027
                     Patient Controlled Injectors Market Forecast to 2027
The patient controlled market was valued 
at US$ 2,969.47 million in 2019 and is 
projected to reach US$  7,505.70 million by 
2027; it is expected to grow at a CAGR of 
12.4% from 2020 to 2027.
The patient controlled injectors are the 
recent invention in the administration of 
injections. There are high-unmet needs of 
people/ HCPs or patients’ requiring the 
patient-controlled injectors, as it has 
greater ease and comfort than any other 
auto-injectors. These are ergonomically 
developed, and the design of patient-
controlled injectors can help optimize self-
care, making it easy for patients to handle 
the system and administer the dosages at 
just one press. 
Lucrative Regional Patient Controlled Injectors Markets
The patient controlled injectors market is expected to witness a significant growth due to increasing 
prevalence of infectious diseases and growing emphasis on superior patient compliance. However, poor 
adoption of injectors in emerging countries is likely to deter the growth of the market during the forecast 
period.
Download Sample Copy @ https://www.theinsightpartners.com/sample/TIPRE00015234/ 
    
Market Insights
Rising Prevalence of Chronic Diseases
Patient controlled Injectors are subcutaneous drug delivery systems that adhere to the body and administer 
larger volumes (more than 2 mL) of a drug over an extended period. With the use of patient-controlled 
injectors, dosing errors, microbial contamination risks, and needle stick injuries can be avoided that are 
caused during parenteral drug administration using injections. In the last few years, the pharmaceutical 
industry has witnessed the introduction of several innovative interventions for the treatment of various 
chronic diseases. However, the majority of the available treatment options require parenteral drug 
administration, frequent dosing, and repeated hospital visits. Therefore, patient controlled injectors are 
preferred for the treatment of chronic diseases where long-term treatment is necessary.
Chronic diseases, such as blood disorder, autoimmune disorders, and various types of cancer, are the leading 
causes of death and disability worldwide. According to the Centers for Disease Control and Prevention, in 
2019, nearly 6 in 10 people suffer from at least one chronic disease in the US.
 
Cardiovascular diseases (CVDs) are a significant cause of mortality globally owing to the hectic lifestyle. As per 
the World Health Organization (WHO), CVDs are the number one cause of death globally, taking an estimated 
17.9 million lives each year. Many biologics are commercially available for the treatment, but the conventional 
drug delivery methods are unable to provide accurate dosage. This augments the use of patient controlled 
injector drug delivery systems that provide targeted drug delivery and prolonged drug residence to the affected 
areas of the cardiovascular system. Hence, the adoption of patient controlled injectors is likely to increase, 
thereby propelling the market growth.
Product-Based Insights
Based on product, the patient controlled injectors market is segmented into electronic wearable injector, 
mechanical wearable injector, and infusion pumps. In 2019, the electronic wearable injector segment held the 
largest share of the market; whereas, the mechanical wearable injector segment is likely to witness the fastest 
growth during the forecast period.
Global Patient Controlled Injectors Market, by Product – 2019 & 2027
Application-Based Insights
Based on application, the patient controlled injectors market is segmented into cancer treatment, auto-immune 
treatment, blood disorders treatment, and others. The cancer treatment segment held the largest share of the 
market in 2019 and is estimated to register the fastest growth during the forecast period.
 
Distribution Channel-Based Insights
Based on distribution channel, the patient controlled injectors market is segmented into hospital pharmacies, retail 
pharmacies, and mail order pharmacies. The hospital pharmacies segment held the largest share of the market in 
2019 and is estimated to register the fastest growth during the forecast period.
The demand for patient controlled injectors increased during the pandemic. Factors such as increased 
patient population, shortage of healthcare resources, and ease of increased the adoption of injectors 
had positive impact on the market by certain extent. However, implementation of physical distancing 
policies and total shut down of businesses in order to prevent the viral infection disrupted the supply 
chain operations, which, in turn caused a negative impact on the market growth.
 
Strategic Insights
Product launches and expansion strategy is commonly adopted by companies to expand their footprint 
worldwide and meet the growing demand. This strategy is most commonly adopted by the market 
players in order to expand its product portfolio.
 
The market players operating in the patient controlled injectors market adopted the strategy of product 
innovation to cater the changing customer demand across the world, which also permits the players to 
maintain their brand name globally.
Patient Controlled Injectors Market – By Product
Electronic Wearable Injector
Mechanical Wearable Injector
Infusion Pumps
Patient Controlled Injectors Market – By Application
Cancer Treatment
Auto-immune Treatment
Blood Disorders Treatment
Others
Patient Controlled Injectors Market – By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Mail Order Pharmacies
 Company Profiles
• Gerresheimer AG
• F. Hoffmann-La Roche Ltd.
• Johnson and Johnson Services, Inc.
• Ypsomed AG
• Westbourne Medical Limited
• Enable Injections
• scPharmaceuticals Inc.
• United Therapeutics Corporation
• BD
Patient Controlled Injectors Market 
 
        
Access Full Research Report at: 
https://www.theinsightpartners.com/reports/patient-controlled-injectors-market/
 
Thank You! 
Thank You!